Affimed(AFMD)

6.90 0.27 4.0724%

今开:6.71昨收:6.63
最高:7.03 最低:6.62
涨停价:0.0跌停价:0.0
总市值:8.20776252E8

Affimed的热门评论

Pharmachoi2020-04-16 20:41

$Affimed(AFMD)$ first Patient Successfully Dosed in First-in-Human Phase 1/2A Study of AFM24 for the Treatment of Advanced EGFR-Expressing Solid Tumors Including Colon, Lung and Other Cancers查看全文

Pharmachoi2020-04-05 11:33

$Affimed(AFMD)$ 2020年4月2日–致力于让患者恢复其与生俱来的抗癌能力的临床阶段免疫肿瘤公司(纳斯达克:AFMD)今天提供了其应对COVID-19冠状病毒大流行持续蔓延的最新运营情况。阿菲迈德还宣布,将于2020年4月28日(星期二)美国东部时间上午8:30召开电话会议,讨论其2019年全年的财务业绩和最近的...查看全文

Pharmachoi2020-04-02 09:31

$Affimed(AFMD)$ Affimed Announces FDA Granted Orphan Drug Designation for Lead Innate Cell Engager AFM13 for the Treatment of T-cell Lymphoma Affimed Announces FDA Granted Orphan Drug Designation for Lead Innate Cell Engager AFM13 for the Treatment of T-cell Lymphoma查看全文

财报披露

Affimed(AFMD)07-01 19:03

$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-21-205507 Act: 34 Size: 392 KB 网页链接查看全文

薛定锷之猫2020-05-15 23:01

$Affimed(AFMD)$ Affimed researchers served as co-authors on an abstract for RO7297089 with scientific collaborators from Genentech, June22公布摘要 个人猜测不会是坏消息查看全文

Affimed(AFMD)2020-05-27 04:40

$Affimed(AFMD)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001319244-20-000072 Act: 34 Size: 128 KB 网页链接查看全文

Pharmachoi2020-04-03 23:12

$Affimed(AFMD)$ $afmd expect preliminary AFM13 data in PTCL at 2020 year-end, with more visibility on an accelerated regulatory path. Initial AFM24 data in EGFR+ solid tumors is expected in late 2020 and could provide additional upside.查看全文

Affimed(AFMD)06-17 04:06

$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-21-192099 Act: 34 Size: 29 KB 网页链接查看全文

先抑后扬06-03 23:33

$Affimed(AFMD)$昨日加仓被套,两药联用的是不是都是坑?脐带血的NK细胞疗效是不是不需要AFM13也很厉害?查看全文

Affimed(AFMD)2020-01-28 22:33

【异动】$Affimed(AFMD)$ 22:33涨幅达4.40%,现价2.85美元查看全文

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35

Affimed的最新评论

Spica07-18 19:54

回复@Takeabreak: 我问了下一位做干眼症的朋友,他是这么回复的“”Eysuvis 应该还不错,但不会成为重磅。重要的原因:lotemax一直被off label用作治疗干眼,$Kala制药(KALA)$ 只是改了一个剂型,把off label变成approved。Lotemax医生可以随便开的,会一定程度限制了Eysuvis销售“//@Takeabreak:...查看全文

山里修炼07-01 21:29

$Affimed(AFMD)$ 又傻逼了!唉查看全文

财报披露

Affimed(AFMD)07-01 19:03

$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-21-205507 Act: 34 Size: 392 KB 网页链接查看全文

Takeabreak06-18 22:39

$安帝君斯(AGEN)$ $Kala制药(KALA)$ $Affimed(AFMD)$ BCYC, CGEN 这些都很强势!守住不动,同时间 XBI往下0.8%+。AMRS更是往上1%。吹票时间到了!![加油]查看全文

Affimed(AFMD)06-17 04:06

$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-21-192099 Act: 34 Size: 29 KB 网页链接查看全文

先抑后扬06-03 23:33

$Affimed(AFMD)$昨日加仓被套,两药联用的是不是都是坑?脐带血的NK细胞疗效是不是不需要AFM13也很厉害?查看全文

Affimed(AFMD)05-21 05:00

$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-21-167904 Act: 34 Size: 131 KB 网页链接查看全文

美股小红书05-17 09:26

而近半年价格已经翻倍的NK细胞疗法企业Affimed(NASDAQ:AFMD)中,公司也持有近5%的股份 $海普瑞(SZ002399)$ $信立泰(SZ002294)$ $天士力(SH600535)$查看全文

美股小红书05-17 09:17

而近半年价格已经翻倍的NK细胞疗法公司Affimed(NASDAQ:AFMD)中,Point72也也持有近5%的股份。 $XD用友网(SH600588)$ $华熙生物(SH688363)$ $新和成(SZ002001)$查看全文

Takeabreak05-14 21:58

$Affimed(AFMD)$ Could Affimed Be a Millionaire-Maker Stock? 网页链接查看全文

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35

Affimed的公告

财报披露

$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-21-205507 Act: 34 Size: 392 KB 网页链接

$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-21-192099 Act: 34 Size: 29 KB 网页链接

$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-21-167904 Act: 34 Size: 131 KB 网页链接

$Affimed(AFMD)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001072613-21-000373 Act: 34 Size: 107 KB 网页链接

$Affimed(AFMD)$ 20-F/A [Amend] Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Accession Number: 0001104659-21-053202 Act: 34 Size: 77 KB 网页链接

$Affimed(AFMD)$ 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Accession Number: 0001047469-21-000956 Act: 34 Size: 8 MB 网页链接

$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-21-117084 Act: 34 Size: 170 KB 网页链接

$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-21-116238 Act: 34 Size: 2 MB 网页链接

$Affimed(AFMD)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-21-050088 Act: 34 Size: 94 KB 网页链接

$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-21-110851 Act: 34 Size: 42 KB 网页链接

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21